Evaluating the corporate social responsibility agenda for high-cost novel therapies: roles for government and civil society
Pharmaceutical CSR strategies may benefit from greater coordination with government and civil society actors. Opportunities for government and civil society actors to take an active role in better aligning CSR activity with patient needs and universal health coverage include promoting greater adoption of alternative corporate structures and providing active external recognition of successful CSR initiatives through reputational and funding awards.
Authors
- Jillian Clare Köhler (ORCID: https://orcid.org/0000-0003-1290-9484)
- Anna Wong (ORCID: https://orcid.org/0000-0001-8163-4088)
- Gul Saeed (ORCID: https://orcid.org/0000-0001-6222-3275)
- Sarah Garner (ORCID: https://orcid.org/0009-0002-4330-0671)
Institutions
- Toronto Public Health (CA)
- University of Toronto (CA)
- World Health Organization Regional Office for Europe (DK)
- Public Health Ontario (CA)
- Ehlers-Danlos Society (US)
Publication Details
- Journal
- Health Research Policy and Systems
- Published
- 2025-11-28
- DOI
- https://doi.org/10.1186/s12961-025-01421-w
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Toronto